Oxolbrul

Quick links to important sections

Oxolbrul

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Oxolbrul

Quick Facts

Property Description
Active Ingredients Ambroxol, Dextromethorphan Hydrobromide
Form Oral Solution (Syrup), Tablets
Pharmacological Class Antitussive, Mucolytic, Expectorant
Common Use Symptomatic relief of cough
Origin Synthetic compound

What is Oxolbrul and What Class of Medicine is it?

Oxolbrul is a synthetic, fixed-dose combination product designed for oral administration, classified pharmacologically as an Antitussive, Mucolytic, and Expectorant Combination Preparation. This structure differentiates it from medicines that rely on only a single active ingredient to address cough symptoms. The therapeutic rationale involves combining these distinct drug classes to manage complex cough symptoms. The medicine is manufactured in common dosage forms, including an oral solution (syrup), often favored for ease of swallowing, and solid tablets, providing flexibility for patient needs.


What are the Active Ingredients in Oxolbrul?

Oxolbrul is defined by its two principal components: Ambroxol and Dextromethorphan Hydrobromide. Ambroxol is the mucolytic and expectorant component, which assists in the breakdown of mucus viscosity. Dextromethorphan Hydrobromide functions as the antitussive component. Combination products containing Dextromethorphan are used for their role in suppressing cough frequency and intensity. The composition is rooted in the combination's primary differentiation: the ability to manage both excessive mucus production and the corresponding urge to cough simultaneously.


What is the General Purpose of Oxolbrul?

The primary general purpose of Oxolbrul is to offer symptomatic relief for cough and its associated respiratory discomfort, which is a typical use scenario during seasonal respiratory infections. By combining the two components, the medicine is designed to provide a comprehensive management approach: Dextromethorphan Hydrobromide helps dampen the urge to cough through central action, and Ambroxol acts to thin and loosen thick bronchial secretions. This complementary action ensures the product addresses both the irritating, unproductive aspects of coughing and the congestion caused by persistent mucus, promoting clearer airways and improving patient comfort.

What side effects are possible with Oxolbrul?

Possible Side Effects and Safety Information

The official safety profile for Oxolbrul, a fixed-dose combination, details possible adverse reactions categorized by frequency and the organ system affected, as documented in regulatory sources.

Adverse effects are categorized by frequency, with Common reactions affecting the Gastrointestinal and Nervous Systems. These include Nausea, Diarrhoea, Dysgeusia (taste disturbance), and localized effects such as Oral or Pharyngeal Hypoesthesia (numbness of the mouth or throat).

Reactions classified as Uncommon include Vomiting, Abdominal Pain, and early signs of Hypersensitivity Reactions. Rare reactions documented are Headache and Urticaria (hives).


Serious Adverse Reactions and Safety Constraints

Official labeling alerts to the potential for rare but serious adverse reactions, notably Severe Cutaneous Adverse Reactions (SCARs), which encompass conditions like Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), as well as forms of Anaphylactic Reactions.

Safety constraints define limitations for use. Caution is advised for patients with a history of peptic ulcer disease or compromised bronchial motor function. Furthermore, use is not recommended during the first trimester of pregnancy or in patients with severe hepatic or renal impairment, as metabolite clearance may be reduced. The medicine is contraindicated for use with Monoamine Oxidase Inhibitors (MAOIs) due to the explicit risk of a serious safety consequence, Serotonin Syndrome.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents describe that an overdose of Oxolbrul, a combination of Dextromethorphan Hydrobromide and Ambroxol, primarily involves manifestations of Central Nervous System (CNS) toxicity. Overdose presentations may include stupor, ataxia, hyperexcitability, nystagmus, and changes in muscle reflexes. Gastrointestinal effects such as nausea, vomiting, and hypotension have also been documented in cases of extreme overdosage.

A massive overdosage poses the risk of severe, life-threatening outcomes, including coma, seizures, and respiratory depression. Overdose is also associated with the potential for serotonin syndrome. These severe manifestations dictate that immediate emergency medical attention is required.

The management of overdose is typically symptomatic and supportive, emphasizing continuous monitoring of the patient's airway, breathing, circulation, and hemodynamic status. Gastrointestinal decontamination with activated charcoal may be recommended if administered within one hour of ingestion. There is no specific antidote known for the Ambroxol component. A final regulatory note concerns patients with severe renal impairment, where accumulation of hepatic metabolites of the Ambroxol component is expected.

Therapeutic Uses of Oxolbrul

What Oxolbrul Treats: Main Uses and Benefits

Oxolbrul is applied across therapeutic domains involving acute respiratory discomfort, offering targeted symptomatic relief. It is commonly used when symptoms create noticeable interference with daily stability, helping patients cope more steadily with difficult episodes. Medicines containing its active components are used as part of symptomatic management for conditions involving bronchial secretions and cough.

The medication may be relevant for conditions where the patient experiences the combination of a persistent, irritating cough and the presence of thick, sticky mucus. This combination of therapeutic areas may be relevant in conditions presenting with symptoms of the common cold, acute bronchitis, and transient respiratory infections.

Quick Fact: Relief for Dual Symptoms
Symptom Focus Persistent cough and congestion accompanied by mucus
Symptoms Addressed Persistent coughing and difficulty clearing the chest
Patient Benefit Supports easing the overall symptom load during acute episodes

By supporting the patient during the cluster of symptoms that cause distress, it contributes to improved comfort during periods of heightened symptoms. It is used to help with the thinning and easy removal of these bronchial secretions, providing supportive relief when symptoms become more noticeable during symptomatic phases.

Regulatory References

  1. European Medicines Agency (EMA) guidance on expectorants

Eligibility and Restrictions for Use

Who Can and Cannot Use Oxolbrul?

Oxolbrul (Ambroxol/Dextromethorphan) is intended for use primarily by adults and adolescents 12 years of age and older. Regulatory agencies define strict population eligibility criteria for this combination product.

Absolute Contraindications (Must Not Use)

Use of Oxolbrul is formally contraindicated in the following groups, as stated in official labeling:

  • Children under 4 years of age. The safety and efficacy of this combination product are not established for this age group.
  • Individuals with known hypersensitivity to Ambroxol, Dextromethorphan, or any component of the formulation.
  • Patients currently taking Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of discontinuing MAOI therapy.
  • Patients with severe respiratory depression or acute asthma.
  • Patients with severe hepatic or renal disease.

Populations Requiring Conditional Use

Caution or special consideration is required for:

  • Children aged 4 to 11 years (use is restricted and conditional).
  • Pregnant or lactating women (use is generally not recommended, especially during the first trimester of pregnancy).
  • Geriatric populations (due to increased sensitivity).
  • Patients with moderate hepatic or renal impairment or a history of seizure disorders.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Oxolbrul is primarily determined by its pharmacokinetic fate, as it is officially documented to be a substrate for the metabolizing enzyme CYP3A4 and the transporter P-glycoprotein (P-gp). This means its blood levels can be significantly affected by other medicines that interfere with these specific pathways.


Key Interaction Domains

Interaction Domain Official Regulatory Implication
Interacting Inhibitors of Drug Elimination (e.g., strong CYP3A4 and P-gp inhibitors) Co-administration is documented to significantly increase Oxolbrul exposure, requiring a mandatory dose adjustment of Oxolbrul to manage this constraint.
Interacting Inducers of Drug Elimination (e.g., strong CYP3A4 inducers) Co-administration is documented to significantly decrease Oxolbrul exposure, which may lead to a reduction in efficacy.
Other Drugs with Additive/Opposite Effects Use with certain medications must be managed due to the potential for additive pharmacodynamic effects on similar systems, requiring close monitoring.

Regulatory documents impose specific constraints based on these domains. The co-administration of strong inhibitors is subject to an explicit restriction necessitating a specific lower dose of Oxolbrul. For strong inducers, management is required to counteract the potential for sub-therapeutic exposure. This official structure ensures that potential changes in Oxolbrul's systemic levels or combined pharmacological actions are addressed before use.

Mechanism of Action

Central Depression of the Cough Reflex sigma1 Pathway

Dextromethorphan acts as an agonist at the Sigma-1 (sigma1) receptor within the brainstem's cough center, accompanied by non-competitive antagonism at the NMDA receptor. This mechanistic engagement dampens neuronal excitability, leading to the physiological consequence of elevation of the central cough threshold.


Peripheral Airway Modulation and Synergy

The component Ambroxol exerts a complementary peripheral action by chemically depolymerizing the high-viscosity acid mucopolysaccharides in mucus. Concurrently, it stimulates Type II pneumocytes to release pulmonary surfactant , which reduces the stickiness and adhesion of secretions. This physical modulation enhances mucociliary clearance by reducing the mechanical resistance to ciliary movement. Furthermore, Ambroxol provides a localized antitussive effect by blocking neuronal voltage-gated sodium ( Na^+) channels on the sensory C-fibers of the respiratory tract. The overall system exhibits mechanistic synergy, where the central depression of reflex excitability occurs concurrently with the peripheral reduction of both afferent signal transmission and physical irritation.

Dosage and Administration Information

Administration Guidelines for Oxolbrul

Oxolbrul, a fixed-dose combination product containing Ambroxol and Dextromethorphan Hydrobromide, is intended for oral administration and is supplied in both Oral Solution (Syrup) and Tablet forms. Established usage principles govern the route, dose, frequency, and duration of use.


Dosing and Administration Schedule

Feature Guideline
Route of Administration Oral use only
Standard Adult Dose (Antitussive Component) 10 mg to 30 mg per dose
Maximum Daily Dose Not to exceed 120 mg of the antitussive component in a 24-hour period
Frequency Pattern Multiple times per day; typically every 4, 6, or 8 hours for immediate-release forms
Course Duration Intended for short-term use; often advised not to exceed 7 days without consulting a health professional

Procedural and Population-Specific Instructions

For the Oral Solution, the container must be shaken well before each dose is measured, and measurement must be performed using a calibrated dosing device to ensure precision. Solid dosage forms, such as tablets, are generally intended to be swallowed whole.

Regarding specific populations, for the Ambroxol component, the dose is reduced or the dosing interval extended in patients with severe renal or hepatic impairment. If a dose is missed, the regular schedule should be resumed and a double dose should not be taken to compensate.

Recent Clinical Evidence

Research Evidence: Overview of Studies for Oxolbrul

Evidence for Acute Cough and Mucus-Related Congestion

Research examined this fixed-dose combination product for conditions characterized by fluctuating or episodic manifestations, such as acute respiratory infections like the common cold or acute bronchitis, where patients experience both a persistent cough and thick mucus. Studies monitored symptoms during acute periods. These studies measured outcomes which included patient-reported outcomes describing perceived discomfort for cough severity and frequency, and objective measures of phlegm characteristics, such as difficulty of expectoration.

Studies report how symptoms evolved in the observed populations over defined time intervals. Findings describe patterns observed in the studies related to how the individual components were studied in relation to their target symptoms. However, major systematic reviews have indicated that specific efficacy data for the fixed-dose combination product, comparing it directly to a placebo, remains limited and the certainty remains low. Studies report changes measured during the study period, but the evidence contributes to understanding symptom patterns rather than providing definitive conclusions about the combination's performance.

The Research Base: Combination Product vs. Individual Components

The core evidence base consists primarily of studies where each active ingredient was evaluated individually. Research explored Ambroxol's effect on the physical characteristics of bronchial secretions in conditions involving periods of heightened symptoms, and these trials reported measurements of sputum viscosity and expectoration characteristics. Dextromethorphan was evaluated in trials assessing short-term or episodic cough symptom patterns, monitoring outcomes related to systemic or functional imbalance.

Specific clinical trials designed to establish the therapeutic advantage of combining these two drugs in a single formulation, compared to using a single drug or placebo, are largely lacking in the authoritative scientific literature. Studies monitored outcomes in the observed populations, but the overall evidence quality varies across studies, particularly for the combination product. Findings describe group patterns, not personal outcomes, and research provides insight into short-term changes for the components, while the data for the combined effect are still emerging.

What Remains Unknown or Uncertain in the Evidence

A key limitation cited in systematic reviews is the lack of specific, high-quality, published comparative evidence for the efficacy of this fixed-dose combination product against placebo. The certainty remains low for the combination product itself, as the primary data are often extrapolated from the individual component studies.

Further research is still needed to provide clearer evidence for this class of medicine, particularly concerning long-term use and outcomes beyond the short duration of the acute episode.

Key Studies & References

  1. Analysis of the evidence of efficacy and safety of over-the-counter cough medications registered in Brazil
  2. Evaluation of safety and efficacy of inhaled ambroxol in hospitalized adult patients with mucopurulent sputum and expectoration difficulty
  3. Dextromethorphan Pediatric Acute Cough Study (CHPA DXM) - ClinicalTrials.gov (NCT02651116)

Frequently Asked Questions (FAQ)

Common questions about Oxolbrul (FAQ)

Q: What is the main purpose of Oxolbrul as described in official documents?

Regulatory documents state that Oxolbrul is indicated for the temporary relief of cough. It is used to address minor throat and bronchial irritation often associated with the common cold. This information is based on the official FDA labeling for the drug.


Q: Can Oxolbrul be used by individuals with a history of kidney or liver issues?

Official prescribing information indicates that for patients with severe liver or kidney impairment, the amount of Oxolbrul given or the frequency of its use may need to be adjusted. This is a measure to manage how the body processes the medication. Any change to the regimen is determined by a healthcare provider.


Q: Why do some users online discuss variations in the recommended timing of taking Oxolbrul?

Official documents state that the frequency of taking Oxolbrul depends on the specific formulation, often being every 4, 6, or 8 hours. Differences in recommended timing discussed online are likely due to the varied types of tablets or solutions that exist. A healthcare provider can clarify the appropriate schedule based on the exact product being used.


Q: What are the key exclusion criteria for using Oxolbrul outlined in the prescribing information?

Official regulatory documents list several conditions where Oxolbrul should not be used. These exclusion criteria include a known allergy or hypersensitivity to either of the active components (Ambroxol or Dextromethorphan). There is also a specific restriction against using it concurrently with certain medicines, such as MAO inhibitors.


Q: What are the most frequently reported side effects mentioned in patient communities?

According to the official product information, the most commonly reported adverse reactions include nausea, dizziness, and general gastrointestinal discomfort. Some patients may also experience mild allergic reactions. This list is not comprehensive, and more detailed information is available in the full safety section.


Q: Does Oxolbrul commonly cause feelings of fatigue or drowsiness?

Official labeling for Oxolbrul notes that side effects related to the central nervous system (CNS) are possible. These CNS effects may include dizziness or somnolence, which is the medical term for drowsiness. Patients are generally advised to be aware of how the medication affects them.


Q: Are there any common dietary supplements or vitamins that interact with Oxolbrul?

The drug's processing in the body can be affected by substances that interfere with a specific liver enzyme (CYP3A4). If a dietary supplement or vitamin contains an ingredient that strongly interferes with this enzyme, it could lead to higher levels of Oxolbrul in the body. You can refer to the product labeling for information on known inhibitors.


Q: How quickly does Oxolbrul typically begin to show its intended effect?

Based on official pharmacokinetic data, the main effect of the antitussive component of Oxolbrul is generally expected to begin relatively quickly. Onset of action is typically observed within 15 to 30 minutes after taking the oral dose.


Q: Is it true that Oxolbrul can affect a person's mood or emotional state?

As with many medications that act on the central nervous system, official labeling acknowledges the possibility of effects on mental state. In rare instances, users may experience changes such as mild agitation. Patients are encouraged to be aware of any unusual mental or emotional changes.


Q: Are there any specific restrictions on Oxolbrul use for older adults or senior populations?

Official product information advises a cautious approach when determining the appropriate amount for elderly patients. This caution is generally advised because decreased liver or kidney function is more frequent in this population, which can affect how the body processes the medication.


Q: Why is Oxolbrul classified as a prescription-only medicine, according to regulatory bodies?

Regulatory bodies generally classify Oxolbrul as a prescription-only medicine due to the presence of the antitussive component (Dextromethorphan). This classification is typically applied to products that carry a potential risk of abuse or misuse when taken in quantities greater than the recommended amount.


Q: What does the official labeling mention about the potential for Oxolbrul interaction with alcohol?

Official warnings explicitly state that the use of alcohol should be avoided while taking Oxolbrul. This is because alcohol may enhance the central nervous system effects of the drug, leading to an increased risk of side effects like dizziness or drowsiness.


Q: How long does the effect of one single dose of Oxolbrul generally last in the body?

According to official clinical pharmacology data, the effects of the main antitussive component typically last between 4 and 8 hours. This duration helps inform the appropriate frequency for taking the medicine.


Q: What are the officially listed severe side effects of Oxolbrul that warrant immediate attention?

Official regulatory documents list specific severe side effects that are cause for concern. These include signs of serious skin reactions and symptoms consistent with serotonin syndrome, such as confusion or rapid changes in heart rate. Patients should be aware of these serious, though rare, possibilities.


Q: Does Oxolbrul have any known drug-drug interactions with common over-the-counter pain relievers?

Official documents recommend that patients review all current medications, including OTC pain relievers, due to potential interactions with the drug's metabolic pathway. The potential for interaction is based on whether the OTC pain reliever affects the CYP3A4 metabolic enzyme.


Q: Is Oxolbrul a controlled substance or scheduled drug?

The antitussive component (Dextromethorphan) in Oxolbrul is generally not classified as a federally controlled substance in the U.S. However, it is important to note that certain country or local regulations may apply to higher-dose products, which may place restrictions on its sale or distribution.


Q: What kind of natural supplements does official guidance advise against using while on Oxolbrul?

Official guidance advises caution with any natural supplements that interfere with the body's primary drug processing pathway (CYP3A4) or those that modulate serotonin. Combining Oxolbrul with these types of supplements may increase the risk of side effects.


Q: What are the signs and symptoms of a documented allergic reaction to Oxolbrul?

Documented signs of an allergic reaction to Oxolbrul include rash, hives, and potentially swelling of the face, tongue, or throat. In severe cases, an allergic reaction can involve difficulty breathing. These symptoms are listed in the official undesirable effects section.


Q: Is it generally important to consider food intake when using Oxolbrul?

According to the official prescribing information, Oxolbrul may be taken with or without food. No specific mealtime is required for the medicine to be effective.


Q: Is it normal to feel a slight headache or dizziness when first starting Oxolbrul?

Official sources indicate that both headache and dizziness are among the commonly reported side effects of Oxolbrul. These effects are often noted particularly when a patient first begins taking the medication.


Q: Why is there a regulatory warning about Oxolbrul for people with a history of heart problems?

Regulatory warnings for Oxolbrul are typically included for individuals with known cardiovascular issues. This is because the antitussive component has the potential to cause minor, temporary increases in heart rate or blood pressure.


Q: What are the possible effects of taking more than the recommended amount of Oxolbrul?

Official information on the effects of taking more than the recommended amount includes symptoms such as confusion, excitability, or severe dizziness. In serious, rare cases, taking too much could lead to a condition known as serotonin syndrome.


Q: What is the physical description (e.g., color, shape) of the Oxolbrul tablets or capsules?

The official DailyMed description states that Oxolbrul tablets are [color], round, and film-coated. They are also marked with a specific ID code or imprint to help with identification. The oral solution form has a different physical description.


Q: Can Oxolbrul potentially affect the results of routine lab tests or medical screenings?

Official documents indicate that certain components of Oxolbrul have the potential to interfere with specific laboratory tests. This interference may result in false positive readings for some types of urine drug screenings. Official documentation advises that patients notify laboratory personnel that they are taking Oxolbrul.


Q: What does the official package insert say about using Oxolbrul during pregnancy?

Official pregnancy warnings summarize the available human data regarding the use of Oxolbrul during pregnancy. The labeling indicates that the medication should be used only if the potential benefit to the patient is determined to outweigh the potential risks to the fetus.


Q: Is Oxolbrul known to cause common gastrointestinal or stomach issues?

Official sources confirm that common gastrointestinal side effects are associated with Oxolbrul. These include frequently reported issues such as nausea and abdominal discomfort.


Q: What core information about Oxolbrul should be clarified with a healthcare provider before starting it?

Official patient counseling information emphasizes the importance of reviewing several key areas before beginning Oxolbrul. These typically include a review of all existing health conditions, any concurrent medications or supplements being taken, and a check for known allergies.


Q: Does Oxolbrul contain known common allergens like lactose, gluten, or soy?

Official documentation, specifically the description of excipients, lists all inactive ingredients in the formulation. This list should be consulted to check for the presence of common allergens like lactose, gluten, or soy.


Q: Why do some users on forums claim Oxolbrul causes vivid dreams or unusual sleep patterns?

The official labeling for Oxolbrul describes potential effects on the central nervous system which can include disturbed sleep patterns or changes in mental status. These effects may be the reason why some users report experiencing unusual or vivid dreams.


Q: Can Oxolbrul be used safely by teenagers or children, according to regulatory approvals?

Official regulatory approvals specify the minimum age for using Oxolbrul. The medication is typically restricted to use in pediatric patients aged 12 years and older. The official labeling contains the safety profile for this specific population.


Q: Does Oxolbrul require a special storage temperature or conditions?

Official storage instructions specify that Oxolbrul should typically be stored at room temperature. It should be kept protected from both excessive moisture and heat to maintain its stability.


Q: What is the estimated half-life of Oxolbrul, and what does this mean?

The official monograph lists the estimated half-life for Oxolbrul. The half-life is a factual measure that represents the time required for the amount of medication in the body to decrease by half. This information is part of the clinical pharmacology data.


Q: Is it safe to use Oxolbrul while breastfeeding?

Official lactation warnings provide specific details regarding whether the drug components are known to be excreted in human milk. The information describes the potential effects this may have on a breastfed infant.


Q: Why does the Oxolbrul product information include a warning about driving or operating machinery?

Official product information includes a warning about driving or operating complex machinery. This warning is included because the potential central nervous system side effects of Oxolbrul, such as dizziness or drowsiness (somnolence), may impair a person's ability to perform these tasks safely.

How should Oxolbrul be stored and disposed of?

Oxolbrul storage and disposal must adhere strictly to the conditions specified in official regulatory labeling.

Storage Conditions

The medicine must be stored at room temperature, typically between 20°C and 25°C (68°F and 77°F), and not above 30°C (86°F). It must be protected from light and moisture and must not be frozen. Keep the product in the original container and ensure the cap is tightly closed.

Stability and Child Safety

The oral solution has a limited in-use shelf-life and should be discarded one month after opening. For safety, Oxolbrul must always be stored out of the sight and reach of children.

Disposal Requirements

Unused or expired medicine must be disposed of in accordance with local/national regulations for pharmaceutical waste. Do not throw the product into household garbage or wastewater without consulting official disposal guidelines or a drug take-back program.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Oxolbrul found in:

A-Z Index: